What the Latest Research Shows About Automated Insulin Delivery Systems

A real-world study following 76 children and adolescents found that switching from multiple daily injections (MDI) to automated insulin delivery systems produced measurable improvements in blood sugar control remarkably fast. Within just 15 days of starting an automated system—either the Medtronic MiniMed 780G or Tandem t:slim X2—young people spent significantly more time with blood sugar in target range.

Time in range (the percentage of the day blood sugar stays between healthy levels) jumped from 62% at baseline to 76.7% after 15 days, and remained at 75.8% after 6 months. Time in tight range improved even more dramatically, climbing from 39.8% to 53.9% within the first two weeks. These improvements continued through the 6-month follow-up period, suggesting that automated systems deliver sustained benefits once users adjust to the new technology.

Not everyone experiences the same degree of improvement when starting automated insulin delivery. The research shows that young people who began with higher baseline blood sugar levels saw the biggest gains. Those with elevated starting HbA1c levels experienced particularly pronounced improvements—gains of over 22% in time-in-range and nearly 17% in tight time-in-range.

This pattern suggests that automated systems are especially effective for people whose blood sugar has been harder to manage with manual injection therapy. However, even those starting with better baseline control still saw meaningful improvements, indicating that automated delivery helps across the board.

Researchers conducted a systematic review comparing automated systems that use ultra-rapid-acting insulins (like FIASP and ultra-rapid lispro) versus those using standard rapid-acting insulins. The good news: both work well. The more nuanced finding is that ultra-rapid insulins do provide a measurable advantage—but it's modest.

Across 16 randomized controlled trials involving 664 participants, automated systems using ultra-rapid insulins were associated with an additional 1% increase in time-in-range compared to systems using standard rapid-acting insulins. While statistically significant, this 1% difference is small in practical terms. The benefits were most consistent in systems with automated bolus correction features and appeared strongest with FIASP specifically.

Both insulin types showed similar safety profiles, with no significant differences in severe low blood sugar events or diabetic ketoacidosis risk between the groups.

Another study looked specifically at how different insulin types handle the blood sugar spike that happens after eating. Researchers compared inhaled technosphere insulin with traditional injected rapid-acting insulin in 122 adults using either multiple daily injections or automated delivery systems.

People using inhaled insulin experienced smaller post-meal blood sugar increases, reached peak glucose levels that were lower, and got back to baseline faster than those using injected insulin. These differences were statistically significant and suggest that insulin formulation and delivery method both play a role in managing meals—though both approaches proved safe, with low blood sugar events remaining rare in both groups.

The latest research consistently supports automated insulin delivery as an effective advancement in type 1 diabetes management, particularly for children and adolescents transitioning from manual injection therapy. Benefits appear quickly and persist over time, with the strongest gains seen in people whose blood sugar was previously harder to control.

While newer, faster-acting insulin formulations do offer incremental improvements, the differences are small. The most important factor appears to be the switch to automated delivery itself. As technology and insulins continue to evolve, the evidence suggests that working with your healthcare team to find the system and insulin combination that fits your lifestyle and goals remains the best approach.

Origin: EMJ (News report). Evidence: News report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.